Indomethacin-enhanced anticancer effect of arsenic trioxide in A549 cell line: Involvement of apoptosis and phospho-ERK and p38 MAPK pathways

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Mandegary, Ali ^a   Torshabi, Maryam ^b,c   Seyedabadi, Mohammad ^b,d   Amirheidari, Bagher ^e   Sharif, Elham ^e   Ghahremani, Mohammad Hossein ^b,f  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d BUSHEHR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CASPASE 3; CELECOXIB; CYCLOOXYGENASE 2; DEXAMETHASONE; INDOMETACIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; ANTINEOPLASTIC AGENT; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; ORGANOARSENIC DERIVATIVE; OXIDE; PTGS2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; LUNG CANCER; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN PHOSPHORYLATION; UPREGULATION; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL PROLIFERATION; CYCLOOXYGENASE 2; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOMETHACIN; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; OXIDES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; RNA, MESSENGER; SULFONAMIDES; TIME FACTORS;

EID: 84890043013     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/237543     Document Type: Article

References (48)

1. Stupp R., Monnerat C., Turrisi A. T. III, Perry M. C., Leyvraz S., Small cell lung cancer: state of the art and future perspectives. Lung Cancer 2004 45 1 105 117 2-s2.0-2942547465 10.1016/j.lungcan.2003.12.006 (Pubitemid 38757838)
2. Schwartz G. K., Combination Cancer Therapy: Modulators and Potentiators 2005 Totowa, NJ, USA Humana Press
3. Cohen M. H., Hirschfeld S., Honig S. F., Ibrahim A., Johnson J. R., O'Leary J. J., White R. M., Williams G. A., Pazdur R., Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 2001 6 1 4 11 2-s2.0-0035135374 10.1634/theoncologist.6-1-4 (Pubitemid 32155810)
4. Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K. I., Nakamura S., Ogawa M., Mitsudomi T., Sugiura T., Takahashi T., Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Research 1998 58 17 3761 3764 2-s2.0-0032170955 (Pubitemid 28405625)
5. Tucker O. N., Dannenberg A. J., Yang E. K., Zhang F., Teng L., Daly J. M., Soslow R. A., Masferrer J. L., Woerner B. M., Koki A. T., Fahey T. J. III, Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Research 1999 59 5 987 990 2-s2.0-0033106051 (Pubitemid 29135954)
6. Hosomi Y., Yokose T., Hirose Y., Nakajima R., Nagai K., Nishiwaki Y., Ochiai A., Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 2000 30 2 73 81 2-s2.0-0033735989 10.1016/S0169-5002(00)00132-X
7. de Groot D. J. A., Timmer T., Spierings D. C. J., Le T. K. P., de Jong S., de Vries E. G. E., Indomethacin-induced activation of the death receptor-mediated apoptosis pathway circumvents acquired doxorubicin resistance in SCLC cells. British Journal of Cancer 2005 92 8 1459 1466 2-s2.0-18944405096 10.1038/sj.bjc.6602516 (Pubitemid 40705013)
8. de Groot D. J. A., Van Der Deen M., Le T. K. P., Regeling A., de Jong S., de Vries E. G. E., Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1. British Journal of Cancer 2007 97 8 1077 1083 2-s2.0-35348913142 10.1038/sj.bjc.6604010 (Pubitemid 47587020)
9. Grösch S., Tegeder I., Niederberger E., Bräutigam L., Geisslinger G., COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. The FASEB Journal 2001 15 14 2742 2744 2-s2.0-0035650943
10. Sánchez-Alcázar J. A., Bradbury D. A., Pang L., Knox A. J., Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways. Lung Cancer 2003 40 1 33 44 2-s2.0-0037378456 10.1016/S0169-5002(02)00530-5 (Pubitemid 36344064)
11. Lasa M., Brook M., Saklatvala J., Clark A. R., Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Molecular and Cellular Biology 2001 21 3 771 780 2-s2.0-0035138742 10.1128/MCB.21.3.771-780.2001 (Pubitemid 32104726)
12. Newton R., Seybold J., Kuitert L. M. E., Bergmann M., Barnes P. J., Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. Journal of Biological Chemistry 1998 273 48 32312 32321 2-s2.0-0033610923 10.1074/jbc.273.48.32312 (Pubitemid 29177179)
13. Henzi I., Walder B., Tramèr M. R., Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesthesia and Analgesia 2000 90 1 186 194 2-s2.0-0033981506 (Pubitemid 30022994)
14. Jagannath S., Durie B. G. M., Wolf J., Camacho E., Irwin D., Lutzky J., McKinley M., Gabayan E., Mazumder A., Schenkein D., Crowley J., Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. British Journal of Haematology 2005 129 6 776 783 2-s2.0-21344469223 10.1111/j.1365-2141.2005.05540.x (Pubitemid 40904528)
15. Richardson P. G., Sonneveld P., Schuster M. W., Irwin D., Stadtmauer E. A., Facon T., Harousseau J. L., Ben-Yehuda D., Lonial S., Goldschmidt H., Reece D., San-Miguel J. F., Bladé J., Boccadoro M., Cavenagh J., Dalton W. S., Boral A. L., Esseltine D. L., Porter J. B., Schenkein D., Anderson K. C., Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine 2005 352 24 2487 2498 2-s2.0-20444433230 10.1056/NEJMoa043445 (Pubitemid 41007864)
16. Hida T., Kozaki K. I., Muramatsu H., Masuda A., Shimizu S., Mitsudomi T., Sugiura T., Ogawa M., Takahashi T., Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clinical Cancer Research 2000 6 5 2006 2011 2-s2.0-0034026144 (Pubitemid 30305099)
17. Sun S. Y., Schroeder C. P., Yue P., Lotan D., Hong W. K., Lotan R., Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations. Cancer Biology and Therapy 2005 4 4 407 413 2-s2.0-25144502891 (Pubitemid 41351257)
18. Cai X., Shen Y. L., Zhu Q., Jia P. M., Yu Y., Zhou L., Huang Y., Zhang J. W., Xiong S. M., Chen S. J., Wang Z. Y., Chen Z., Chen G. Q., Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000 14 2 262 270 2-s2.0-0033974883 (Pubitemid 30095381)
19. Bode A. M., Dong Z., The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Critical Reviews in Oncology/Hematology 2002 42 1 5 24 2-s2.0-0036118599 10.1016/S1040-8428(01) 00215-3 (Pubitemid 34229146)
20. Mandegary A., Mehrabani M., Effects of arsenic trioxide, all-trans-retinoic acid and dexamethasone on NB4 cell line. DARU, Journal of Pharmaceutical Sciences 2010 18 4 303 309 2-s2.0-79251480397
21. Mandegary A., Hosseini R., Ghaffari S. H., Alimoghaddam K., Rostami S., Ghavamzadeh A., Ghahremani M. H., The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide. Annals of Oncology 2010 21 9 1884 1890 2-s2.0-77956127094 10.1093/annonc/mdq034
22. Jin H. O., Seo S. K., Woo S. H., Lee H. C., Kim E. S., Yoo D. H., Lee S. J., An S., Choe T. B., Kim J. I., Hong S. I., Rhee C. H., Park I. C., A combination of sulindac and arsenic trioxide synergistically induces apoptosis in human lung cancer H1299 cells via c-Jun NH2-terminal kinase-dependent Bcl-xL phosphorylation. Lung Cancer 2008 61 3 317 327 2-s2.0-51049098335 10.1016/j.lungcan.2008.01.002
23. Lin L. M., Li B. X., Xiao J. B., Lin D. H., Yang B. F., Synergistic effect of all-trans-retinoic acid and arsenic trioxide on growth inhibition and apoptosis in human hepatoma, breast cancer, and lung cancer cells in vitro. World Journal of Gastroenterology 2005 11 36 5633 5637 2-s2.0-28044439606
24. Han Y. H., Kim S. Z., Kim S. H., Park W. H., Induction of apoptosis in arsenic trioxide-treated lung cancer A549 cells by buthionine sulfoximine. Molecules and Cells 2008 26 2 158 164 2-s2.0-53749094063
25. Navidpour L., Shafaroodi H., Abdi K., Amini M., Ghahremani M. H., Dehpour A. R., Shafiee A., Design, synthesis, and biological evaluation of substituted 3-alkylthio-4,5-diaryl-4H-1,2,4-triazoles as selective COX-2 inhibitors. Bioorganic and Medicinal Chemistry 2006 14 8 2507 2517 2-s2.0-33644749178 10.1016/j.bmc.2005.11.029 (Pubitemid 43343637)
26. Brown J. R., DuBois R. N., Cyclooxygenase as a target in lung cancer. Clinical Cancer Research 2004 10 12, part 12 4266s 4269s 2-s2.0-3042665905 10.1158/1078-0432.CCR-040014 (Pubitemid 38812460)
27. Hirsch F. R., Lippman S. M., Advances in the biology of lung cancer chemoprevention. Journal of Clinical Oncology 2005 23 14 3186 3197 2-s2.0-19844371226 10.1200/JCO.2005.14.209 (Pubitemid 46211343)
28. Nutt L. K., Gogvadze V., Uthaisang W., Mirnikjoo B., McConkey D. J., Orrenius S., Indirect effects of Bax and Bak initiate the mitochondrial alterations that lead to cytochrome c release during arsenic trioxide-induced apoptosis. Cancer Biology and Therapy 2005 4 4 459 467 2-s2.0-23844468272 (Pubitemid 41351266)
29. Schroeder C. P., Kadara H., Lotan D., Woo J. K., Lee H. Y., Hong W. K., Lotan R., Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells. Cancer Research 2006 66 19 9762 9770 2-s2.0-33750318681 10.1158/0008-5472.CAN- 05-4124 (Pubitemid 44623678)
30. Soriano A. F., Helfrich B., Chan D. C., Heasley L. E., Bunn P. A. Jr., Chou T. C., Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Research 1999 59 24 6178 6184 2-s2.0-0033572578 (Pubitemid 30035640)
31. Grösch S., Maier T. J., Schiffmann S., Geisslinger G., Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. Journal of the National Cancer Institute 2006 98 11 736 747 2-s2.0-33745238704 10.1093/jnci/djj206 (Pubitemid 43983297)
32. Han S. S., Kim K., Hahm E. R., Park C. H., Kimler B. F., Lee S. J., Lee S. H., Kim W. S., Jung C. W., Park K., Kim J., Yoon S. S., Lee J. H., Park S., Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. Journal of Cellular Biochemistry 2005 94 4 695 707 2-s2.0-26444595244 10.1002/jcb.20337 (Pubitemid 41420269)
33. Verma A., Mohindru M., Deb D. K., Sassano A., Kambhampati S., Ravandi F., Minucci S., Kalvakolanul D. V., Platanias L. C., Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. Journal of Biological Chemistry 2002 277 47 44988 44995 2-s2.0-0037160016 10.1074/jbc.M207176200 (Pubitemid 36159097)
34. Dhillon A. S., Hagan S., Rath O., Kolch W., MAP kinase signalling pathways in cancer. Oncogene 2007 26 22 3279 3290 2-s2.0-34248583886 10.1038/sj.onc.1210421 (Pubitemid 46763021)
35. Xia Z., Dickens M., Raingeaud J., Davis R. J., Greenberg M. E., Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995 270 5240 1326 1331 2-s2.0-0028880006
36. Wang X., Martindale J. L., Holbrook N. J., Requirement for ERK activation in cisplatin-induced apoptosis. Journal of Biological Chemistry 2000 275 50 39435 39443 2-s2.0-0034671751 10.1074/jbc.M004583200 (Pubitemid 32058968)
37. Park J. H., Kim E. J., Jang H. Y., Shim H., Lee K. K., Jo H. J., Kim H. J., Yang S. H., Jeong E. T., Kim H. R., Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. Oncology Reports 2008 20 2 379 384 2-s2.0-48749127647 10.3892/or-00000018
38. Maity P., Bindu S., Dey S., Goyal M., Alam A., Pal C., Mitra K., Bandyopadhyay U., Indomethacin, a non-steroidal anti-inflammatory drug, develops gastropathy by inducing reactive oxygen species-mediated mitochondrial pathology and associated apoptosis in gastric mucosa: a novel role of mitochondrial aconitase oxidation. Journal of Biological Chemistry 2009 284 5 3058 3068 2-s2.0-59149086582 10.1074/jbc.M805329200
39. Loveridge C. J., MacDonald A. D. H., Thoms H. C., Dunlop M. G., Stark L. A., The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF- B. Oncogene 2008 27 18 2648 2655 2-s2.0-42249089519 10.1038/sj.onc.1210891 (Pubitemid 351550873)
40. Zhang Y. J., Bao Y. J., Dai Q., Yang W. Y., Cheng P., Zhu L. M., Wang B. J., Jiang F. H., MTOR signaling is involved in indomethacin and nimesulide suppression of colorectal cancer cell growth via a COX-2 independent pathway. Annals of Surgical Oncology 2011 18 2 580 588 2-s2.0-79951553930 10.1245/s10434-010-1268-9
41. Zhang G. S., Tu C. Q., Zhang G. Y., Zhou G. B., Zheng W. L., Indomethacin induces apoptosis and inhibits proliferation in chronic myeloid leukemia cells. Leukemia Research 2000 24 5 385 392 2-s2.0-0343293999 10.1016/S0145-2126(99) 00198-8 (Pubitemid 30227238)
42. Caicedo-Granados E. E., Wuertz B. R., Marker P. H., Lee G. S., Ondrey F. G., The effect of indomethacin on paclitaxel sensitivity and apoptosis in oral squamous carcinoma cells: the role of nuclear factor- b inhibition. Archives of Otolaryngology-Head and Neck Surgery 2011 137 8 799 805 2-s2.0-84860397236 10.1001/archoto.2011.131
43. Draper M. P., Martell R. L., Levy S. B., Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. British Journal of Cancer 1997 75 6 810 815 2-s2.0-0031053478
44. Lin L. M., Li B. X., Xiao J. B., Lin D. H., Yang B. F., Synergistic effect of all-trans-retinoic acid and arsenic trioxide on growth inhibition and apoptosis in human hepatoma, breast cancer, and lung cancer cells in vitro. World Journal of Gastroenterology 2005 11 36 5633 5637 2-s2.0-28044439606
45. Dai J., Weinberg R. S., Waxman S., Jing Y., Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999 93 1 268 277 2-s2.0-0032933610 (Pubitemid 29019412)
46. Maeda H., Hori S., Ohizumi H., Segawa T., Kakehi Y., Ogawa O., Kakizuka A., Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death and Differentiation 2004 11 7 737 746 2-s2.0-3543084996 10.1038/sj.cdd.4401389 (Pubitemid 39023120)
47. Pan J. S., Hong M. Z., Ren J. L., Reactive oxygen species: a double-edged sword in oncogenesis. World Journal of Gastroenterology 2009 15 14 1702 1707 2-s2.0-65649085279 10.3748/wjg.15.1702
48. Matsuzawa A., Ichijo H., Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochimica et Biophysica Acta 2008 1780 11 1325 1336 2-s2.0-49349083531 10.1016/j.bbagen.2007.12.011